EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Alexander Röth iD, Christopher J Patriquin, Jeff Szer, Louis Terriou, Ami S Patel, Jesse Metzger, Philippe Gustovic, Jun-Ichi Nishimura iD, Robert A Brodsky iD

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70268 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Alexander Röth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Ge…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available. Pivotal trials have demonstrated durable long‐term efficacy, safety, and improved survival, and increasing real‐world evidence is required. This analysis utilized data from the International PNH Registry (NCT01374360) to evaluate the real‐world effectiveness and safety of ravulizumab, and to assess baseline characteristics at treatment initiation. Adults (aged 18–65 years) enrolled in the registry as of July 1, 2024, who were treated with ravulizumab for ≥ 6 months were included and stratified by prior eculizumab use (eculizumab‐experienced and C5i‐naive). Ravulizumab treatment outcomes were assessed for up to 24 months and included change in lactate dehydrogenase (LDH) ratio from baseline, transfusion avoidance, and adverse event rates. Data for 203 eculizumab‐experienced and 23 C5i‐naive patients were analyzed. During treatment, LDH ratio was maintained near normal (< 1.5 × the upper limit of normal in both groups); 86.8% of eculizumab‐experienced and 76.5% of C5i‐naive patients were transfusion‐independent, and a low rate of major adverse vascular events was reported (eculizumab‐experienced, 0.4 per 100 person‐years; C5i‐naive, no events). These findings reinforce the pivotal trial outcomes and demonstrate the effectiveness and safety of ravulizumab in the real‐world setting, further supporting ravulizumab as the first‐line treatment of choice for patients with PNH, where available. Trial Registration: International PNH Registry: NCT01374360

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHemoglobinuria, ParoxysmalAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultL-Lactate DehydrogenaseRegistriesTreatment Outcome

Stichwörter der Autor:innen

C5complement inhibitionparoxysmal nocturnal hemoglobinuriaravulizumabreal‐world outcomes

Substanzen

Antibodies, Monoclonal, HumanizedL-Lactate Dehydrogenaseravulizumab

Autor:innen und Institutionen

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Division of Medical Oncology and Hematology, University Health Network, Toronto, Ontario, Canada.
  • Department of Clinical Hematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Service de Médecine Interne et d'Immunologie Clinique, CHU Lille, Lille, France.
  • Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Parexel, Newton, Massachusetts, USA.

ORCID-Profile: Alexander Röth, Jun-Ichi Nishimura, Robert A Brodsky

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Röth, A., Patriquin, C. J., Szer, J., Terriou, L., Patel, A. S., Metzger, J., Gustovic, P., Nishimura, J. I., & Brodsky, R. A. (2026). Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry. American Journal of Hematology. https://doi.org/10.1002/ajh.70268

Vancouver

Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, et al. Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry. American Journal of Hematology. 2026. doi:10.1002/ajh.70268

BibTeX
@article{Rth2026,
  author = {Röth, Alexander and Patriquin, Christopher J and Szer, Jeff and Terriou, Louis and Patel, Ami S and Metzger, Jesse and Gustovic, Philippe and Nishimura, Jun-Ichi and Brodsky, Robert A},
  title = {Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70268}
}
Kostenlos starten →